Skip to main content

Advertisement

SpringerLink
Log in

Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?

  • Mini Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Chronic inflammation is supposed to be an important mediator of cardiometabolic dysfunctions seen in type 2 diabetes. In this mini-review, we collected evidence (PubMed) from randomized controlled trials (through March 2016) evaluating the effect of anti-inflammatory drugs on indices of glycemic control and/or cardiovascular events in people with type 2 diabetes. Within the last 25 years, many anti-inflammatory drugs have been tested in type 2 diabetes, including hydroxychloroquine, anti-tumor necrosis factor therapies (etanercept and infliximab), salsalate, interleukin-1 antagonists (anakinra, canakinumab, gevokizumab, LY2189102), and CC-R2 antagonists. Despite being promising, the observed effects on HbA1c or glucose control remain rather modest in most clinical trials, especially with the new drugs. There are many trials underway with anti-inflammatory agents to see whether patients with cardiovascular diseases and/or type 2 diabetes may have clinical benefit from marked reductions in circulating inflammatory markers. Until now, a large trial with losmapimod (a p38 inhibitor) among patients with acute myocardial infarction, including one/third of diabetic patients, showed no reduction in the risk of major ischemic cardiovascular events. Further evidence is warranted in support of the concept that targeting inflammation pathways may ameliorate glycemic control and also reduce cardiovascular complications in type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. G.S. Hotamisligil, N.S. Shargill, B.M. Spiegelman, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91 (1993)

    Article  CAS  PubMed  Google Scholar 

  2. G.S. Hotamisligil, A. Budavari, D. Murray, B.M. Spiegelman, Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-alpha. J. Clin. Investig. 94, 1543–1549 (1994)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. P. Libby, Inflammation in atherosclerosis. Nature 420, 868–874 (2002)

    Article  CAS  PubMed  Google Scholar 

  4. K. Esposito, D. Giugliano, The metabolic syndrome and inflammation: association or causation? Nutr. Metab. Cardiovasc. Dis. 14, 228–232 (2004)

    Article  CAS  PubMed  Google Scholar 

  5. C. Belizna, Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun. Rev. 14, 358–362 (2015)

    Article  CAS  PubMed  Google Scholar 

  6. Y.C Kaplan, J. Ozsarfati, C. Nickel, G. Koren, Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. (2015 Dec 23). doi: 10.1111/bcp.12872. [Epub ahead of print]

  7. A. Quatraro, G. Consoli, M. Magno et al., Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann. Intern. Med. 112, 678–681 (1990)

    Article  CAS  PubMed  Google Scholar 

  8. H.C. Gerstein, K.E. Thorpe, D.W. Taylor, R.B. Haynes, The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Res. Clin. Pract. 55, 209–219 (2002)

    Article  CAS  PubMed  Google Scholar 

  9. A. Pareek, N. Chandurkar, N. Thomas et al., Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr. Med. Res. Opin. 30, 1257–1266 (2014)

    Article  CAS  PubMed  Google Scholar 

  10. M.C. Wasko, H.B. Hubert, V.B. Lingala, J.R. Elliott, M.E. Luggen, J.F. Fries, M. Ward, Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298, 187–193 (2007)

    Article  CAS  PubMed  Google Scholar 

  11. T.S. Sharma, M.C. Wasko, X. Tang, D. Vedamurthy, X. Yan, J. Cote, A. Bili, Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J. Am. Heart. Assoc. 4, 5 (2016)

    Google Scholar 

  12. M.A. Gonzalez-Gay, C. Gonzalez-Juanatey, T.R. Vazquez-Rodriguez et al., Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann. N. Y. Acad. Sci. 1193, 153–159 (2010)

    Article  CAS  PubMed  Google Scholar 

  13. J. Channual, J.J. Wu, F.J. Dann, Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol. Ther. 22, 61–73 (2009)

    Article  PubMed  Google Scholar 

  14. E. Parmentier-Decrucq, A. Duhamel, O. Ernst et al., Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn’s disease. Inflamm. Bowel Dis. 15, 1476–1484 (2009)

    Article  PubMed  Google Scholar 

  15. F. Ofei, S. Hurel, J. Newkirk, M. Sopwith, R. Taylor, Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881–885 (1996)

    Article  PubMed  Google Scholar 

  16. H. Dominguez, H. Storgaard, C. Rask-Madsen et al., Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42, 517–525 (2005)

    Article  CAS  PubMed  Google Scholar 

  17. N. Esser, N. Paquot, A.J. Scheen, Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin. Investig. Drugs 24, 283–307 (2015)

    Article  CAS  PubMed  Google Scholar 

  18. Q. Javed, I. Murtaza, Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. 22, 323–327 (2013)

    Article  PubMed  Google Scholar 

  19. J. Zhang, F. Xie, H. Yun, et al, Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann. Rheum. Dis. (2016 Jan 20). doi: 10.1136/annrheumdis-2015-207870. [Epub ahead of print]

  20. S.E. Shoelson, J. Lee, A.B. Goldfine, Inflammation and insulin resistance. J. Clin. Investig. 116, 1793–1801 (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. M.J. Yin, Y. Yamamoto, R.B. Gaynor, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77–80 (1998)

    Article  CAS  PubMed  Google Scholar 

  22. T.D. Gilmore, Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680–6684 (2006)

    Article  CAS  PubMed  Google Scholar 

  23. A.B. Goldfine, V. Fonseca, K.A. Jablonski, L. Pyle, M.A. Staten, S.E. Shoelson, TINSAL-T2D (TargetingInflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346–357 (2010)

    Article  PubMed  PubMed Central  Google Scholar 

  24. A.B. Goldfine, V. Fonseca, K.A. Jablonski, Y.D. Chen, L. Tipton, M.A. Staten, S.E. Shoelson, Targeting inflammation using salsalate in type 2 diabetes study team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 159, 1–12 (2013)

    Article  PubMed  PubMed Central  Google Scholar 

  25. A.B. Goldfine, J.S. Buck, C. Desouza et al., Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care 36, 4132–4139 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. K. Maedler, P. Sergeev, F. Ris et al., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Investig. 110, 851–860 (2002)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. C.M. Larsen, M. Faulenbach, A. Vaag, A. Vølund, J.A. Ehses, B. Seifert, T. Mandrup-Poulsen, M.Y. Donath, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517–1526 (2007)

    Article  CAS  PubMed  Google Scholar 

  28. C. Herder, E. Dalmas, M. Böni-Schnetzler, M.Y. Donath, The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol. Metab. 26, 551–563 (2015)

    Article  CAS  PubMed  Google Scholar 

  29. H.J. Lachmann, I. Kone-Paut, J.B. Kuemmerle-Deschner, K.S. Leslie, E. Hachulla, P. Quartier, X. Gitton, A. Widmer, N. Patel, P.N. Hawkins, Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009)

    Article  CAS  PubMed  Google Scholar 

  30. P.M. Ridker, C.P. Howard, V. Walter, on behalf of the CANTOS Pilot Investigative Group et al., Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen. A phase IIb randomized, placebo-controlled trial. Circulation 126, 2739–2748 (2012)

    Article  CAS  PubMed  Google Scholar 

  31. C. Cavelti-Weder, A. Babians-Brunner, C. Keller, M.A. Stahel, M. Kurz-Levin, H. Zayed, A.M. Solinger, T. Mandrup-Poulsen, C.A. Dinarello, M.Y. Donath, Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654–1662 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. J. Sloan-Lancaster, E. Abu-Raddad, J. Polzer, J.W. Miller, J.C. Scherer, A. De Gaetano, J.K. Berg, W.H. Landschulz, Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239–2246 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. N.A. Di Prospero, E. Artis, P. Andrade-Gordon, D.L. Johnson, N. Vaccaro, L. Xi, P. Rothenberg, CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes. Metab. 16, 1055–1064 (2014)

    Article  PubMed  Google Scholar 

  34. S. Kaptoge, E. Di Angelantonio, G. Lowe, M.B. Pepys, S.G. Thompson, R. Collins, J. Danesh, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132–140 (2010)

    Article  PubMed  Google Scholar 

  35. P.M. Ridker, T. Thuren, A. Zalewski, P. Libby, Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011)

    Article  CAS  PubMed  Google Scholar 

  36. P.M. Ridker, Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 7(Suppl 1), 332–339 (2009)

    Article  CAS  PubMed  Google Scholar 

  37. P.M. Ridker, T.F. Lüscher, Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 35, 1782–1791 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. M.L. O’Donoghue, R. Glaser, M.A. Cavender, LATITUDE-TIMI 60 Investigators et al., Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315, 1591–1599 (2016)

    Article  PubMed  Google Scholar 

  39. L.K. Newby, M.S. Marber, C. Melloni et al., SOLSTICE investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384, 1187–1195 (2014)

    Article  CAS  PubMed  Google Scholar 

  40. M.Y. Donath, Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia 59, 679–682 (2016)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical, Surgical, Neurological, Metabolic Sciences and Aging, Endocrinology and Metabolic Diseases Unit, Second University of Naples, Piazza L. Miraglia n° 2, 80138, Naples, Italy

    Maria Ida Maiorino, Giuseppe Bellastella & Dario Giugliano

  2. Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy

    Katherine Esposito

Authors
  1. Maria Ida Maiorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Bellastella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dario Giugliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katherine Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Ida Maiorino.

Ethics declarations

Conflict of Interest

D. G. and K. E. received speaker fees from Lilly, SANOFI, and NOVARTIS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maiorino, M.I., Bellastella, G., Giugliano, D. et al. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?. Endocrine 55, 360–365 (2017). https://doi.org/10.1007/s12020-016-0993-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-0993-7

Keywords

Search

Navigation